Clinical Use of Tolmetin Sodium in Patients with Ankylosing Spondylitis: A Review
- 1 July 1983
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 23 (7) , 301-308
- https://doi.org/10.1002/j.1552-4604.1983.tb02740.x
Abstract
The efficacy and safety of tolmetin sodium in the management of ankylosing spondylitis are presented in a review of published and unpublished data. In both open and controlled clinical studies, tolmetin was superior to placebo and equal to indomethacin in its capacity to relieve pain, inflammation, and other symptoms of ankylosing spondylitis (AS). Objective and subjective assessments showed that both tolmetin sodium and indomethacin provided significant therapeutic benefits to patients with AS. In AS, the two drugs showed similar adverse reaction profiles. Adverse reactions with both drugs were minimal and predominantly affected the gastrointestinal tract; in most cases these symptoms cleared spontaneously without discontinuing the drugs.Keywords
This publication has 6 references indexed in Scilit:
- TolmetinDrugs, 1978
- Ankylosing spondylitisPostgraduate Medicine, 1977
- Pharmacokinetics of tolmetin with and without concomitant administration of antacid in manEuropean Journal of Clinical Pharmacology, 1977
- Tolmetin Sodium, a New Anti‐Arthritis Drug: Double‐Blind and Long‐Term StudiesJournal of the American Geriatrics Society, 1976
- Evaluation of tolmetin in the treatment of active chronic rheumatoid arthritis open and controlled double-blind studiesCurrent Medical Research and Opinion, 1976
- Results of a One‐Year Trial of Tolmetin in Patients with Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 1975